Fact CheckerSign in

NCT06963515Not yet recruiting

Cutting-edge IMAGING Technologies to Improve the SAFEty and the Sustainability of LUNG Cancer Screening and the Accuracy of Non-invasive Lung Nodules Characterization

Source: ClinicalTrials.gov · Last updated 9 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Low-dose computed tomography (LDCT) is used in individuals at high risk of developing lung cancer (smokers over 50 years of age), as it allows for the identification of pulmonary nodules, which, in a small percentage of cases, may represent early-stage lung cancer. However, according to LUNG-RADS guidelines, individuals undergoing screening must repeat multiple LDCT scans, as the comparison between successive LDCT scans enables the assessment of existing nodules' progression and the identification of newly developed pulmonary nodules. This results in cumulative exposure to ionizing radiation, increasing the risk of radiation-induced cancers. This study addresses, through the implementation of new imaging techniques utilizing the latest and most advanced technological innovation (high-field 3T Magnetic Resonance Imaging (MRI) with artificial intelligence), the critical challenge of reducing radiation exposure in current LDCT-based screening programs, proposing the use of MRI as an alternative screening method to LDCT.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
250 (estimated)
First submitted
19 Feb 2025
Start date
20 Jun 2025
Primary completion date
20 Jun 2027
Lead sponsor
IRCCS San Raffaele
Diseases
Lung cancer
NCT number
NCT06963515

What you commit to

  • Study type: Observational
  • Planned participants: 250
  • From 20 Jun 2025 to the primary completion date, 20 Jun 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • presence of metallic implants likely to hamper MRI image quality

Age

  • Age \< 18 years

Other

  • contraindication to MRI
  • inability to hold breath for 15-20 seconds
  • claustrophobia
  • refusal to participate in the study

Who the study is looking for

  • Age ≥ 18 years
  • Indication to first lung cancer screening with LDCT according to international guidelines
  • Indication to repeated lung cancer screening with LDCT according to international guidelines

Age in the registry: 18 years to 100 years · Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.